{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:36:19Z","timestamp":1793975779608,"version":"4.8.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001449","name":"Alzheimer's Disease Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013278","name":"EU Joint Programme \u2013 Neurodegenerative Disease Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013278","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.lanepe.2026.101757","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T16:01:44Z","timestamp":1782230504000},"page":"101757","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["From Target Engagement to Treatment Governance: The Evolving Role of Amyloid PET in Anti-Amyloid Therapy"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-0479","authenticated-orcid":false,"given":"Massimo","family":"Filippi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6544-410X","authenticated-orcid":false,"given":"Giordano","family":"Cecchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8440-1036","authenticated-orcid":false,"given":"Alma","family":"Ghirelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1492-7221","authenticated-orcid":false,"given":"Edoardo G.","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2063-7735","authenticated-orcid":false,"given":"Giulia","family":"Rugarli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Pisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Maria","family":"Samanes Gajate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5806-1856","authenticated-orcid":false,"given":"Arturo","family":"Chiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Agosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanepe.2026.101757_bib1","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.lanepe.2026.101757_bib2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanepe.2026.101757_bib5","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S1474-4422(23)00447-7","article-title":"European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders","volume":"23","author":"Frisoni","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.lanepe.2026.101757_bib6","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(25)01294-2","article-title":"New landscape of the diagnosis of Alzheimer\u2019s disease","volume":"406","author":"Frisoni","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.lanepe.2026.101757_bib9","article-title":"The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer\u2019s disease: an EADC-EC viewpoint","volume":"29","author":"Jonsson","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.lanepe.2026.101757_bib10","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10072-023-06958-8","article-title":"A new national survey of centers for cognitive disorders and dementias in Italy","volume":"45","author":"Bacigalupo","year":"2024","journal-title":"Neurol Sci"},{"key":"10.1016\/j.lanepe.2026.101757_bib11","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1007\/s00259-025-07237-8","article-title":"Capacity for brain amyloid PET in Germany: results from the 1st survey on nuclear brain imaging in Germany","volume":"52","author":"Buchert","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.lanepe.2026.101757_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14338","article-title":"Updated appropriate use criteria for amyloid and tau PET: a report from the Alzheimer\u2019s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup","volume":"21","author":"Rabinovici","year":"2025","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanepe.2026.101757_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70997","article-title":"Treatment-related amyloid clearance (TRAC): a framework to characterize patients in the era of anti-amyloid therapies","volume":"21","author":"La Joie","year":"2025","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanepe.2026.101757_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET","volume":"11","author":"Klunk","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanepe.2026.101757_bib15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jalz.2014.06.006","article-title":"The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey","volume":"11","author":"Bocchetta","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanepe.2026.101757_bib16","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3233\/JAD-220333","article-title":"The clinical use of Alzheimer\u2019s disease biomarkers in patients with mild cognitive impairment: a European Alzheimer\u2019s Disease Consortium Survey","volume":"89","author":"Caprioglio","year":"2022","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.lanepe.2026.101757_bib17","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1038\/s41591-025-03622-w","article-title":"Plasma phospho-tau217 for Alzheimer\u2019s disease diagnosis in primary and secondary care using a fully automated platform","volume":"31","author":"Palmqvist","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.lanepe.2026.101757_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/alz70856_106489","article-title":"Association of occipital amyloid PET burden with ARIA-E: Exploratory analyses in three clinical trials of donanemab","volume":"21","author":"Kennedy","year":"2025","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanepe.2026.101757_bib19","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamaneurol.2025.0065","article-title":"Amyloid-related imaging abnormalities with donanemab in early symptomatic alzheimer disease: secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials","volume":"82","author":"Zimmer","year":"2025","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.lanepe.2026.101757_bib20","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanepe.2026.101757_bib21","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.lanepe.2026.101757_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100150","article-title":"Donanemab: appropriate use recommendations","volume":"12","author":"Rabinovici","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.lanepe.2026.101757_bib23","doi-asserted-by":"crossref","first-page":"101609","DOI":"10.1016\/j.lanepe.2026.101609","article-title":"Anti-amyloid therapies and the transformation of Alzheimer\u2019s care pathways: early lessons from the frontline","volume":"64","author":"Filippi","year":"2026","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101757_bib24","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13195-026-02015-6","article-title":"Real-world implementation of lecanemab and donanemab in an Italian memory center: a 1-year experience","volume":"18","author":"Agosta","year":"2026","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.lanepe.2026.101757_bib26","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1177\/13872877251323231","article-title":"Cost-effectiveness of diagnosing and treating patients with early Alzheimer\u2019s disease with anti-amyloid treatment in a clinical setting","volume":"104","author":"Wimo","year":"2025","journal-title":"J Alzheimers Dis"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226001699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226001699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T08:27:46Z","timestamp":1785745666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776226001699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":21,"alternative-id":["S2666776226001699"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101757","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From Target Engagement to Treatment Governance: The Evolving Role of Amyloid PET in Anti-Amyloid Therapy","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101757","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101757"}}